MDx Firm Atossa Files for IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Atossa Genetics today filed a preliminary prospectus with the US Securities and Exchange Commission to raise up to $17.6 million from an initial public offering.

Proceeds from the offering will be used to create a cytology and molecular diagnostics laboratory focused on breast cancer, and to manufacture and launch its FDA-cleared Mammary Aspirate Specimen Cytology Test System in the Northwestern US, the Seattle-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.